Virtual Library

Start Your Search

Nektarios Anagnostopoulos



Author of

  • +

    EP1.01 - Advanced NSCLC (ID 150)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Advanced NSCLC
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.01-90 - The Prognostic Role of Mean Platelet Volume in Patients with Advanced Non-Small Cell Lung Cancer (Now Available) (ID 1039)

      08:00 - 18:00  |  Author(s): Nektarios Anagnostopoulos

      • Abstract
      • Slides

      Background

      Previous studies suggest the potential correlation between increased mean platelet volume (MPV) and survival in non-small cell lung cancer (NSCLC), but results are often contradictory. We herein aimed to further evaluate the prognostic value of MPV in patients with advanced-stage NSCLC in the real-world setting of a tertiary referral oncology center.

      Method

      Demographic, clinicopathological and laboratory data (including complete blood count parameters) of 30 patients with stage IIIB or IV NSCLC were retrieved from the Lung Cancer registry of the Oncology Clinic of Sotiria Athens General Hospital and analyzed. All the above variables (including MPV) were correlated to each other, as well as with overall survival (OS) and progression-free survival (PFS).

      Result

      Mean patients’ age was 68,5 (SD=7,5) years. The majority of patients were male (76.7%), had positive smoking history (90%), squamous cell carcinoma (53.3%), and stage IV disease (76.7%). No statistically significant correlations between survival and sex, age, smoking history or tumor histology (squamous cell carcinoma versus adenocarcinoma), or between MPV and histology were noted. Worse performance status (p=0.004) and higher white blood cell count (p=0.01) were correlated with reduced OS, while increased MPV was strongly correlated both with OS and PFS (p<0.0001 in both cases).

      Conclusion

      Increased MPV may correlate with improved survival of patients with NSCLC, thus potentially representing a marker of favorable prognosis. Our study findings warrant confirmation in larger prospective series

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    EP1.13 - Staging (ID 203)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Staging
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.13-02 - Negative Predictive Value of EBUS-TBNA for Mediastinal Staging of Non-Small Cell Lung Cancer (Now Available) (ID 1037)

      08:00 - 18:00  |  Author(s): Nektarios Anagnostopoulos

      • Abstract
      • Slides

      Background

      Mediastinal staging must precede surgery in patients with resectable non-small cell lung cancer (NSCLC). According to current guidelines, minimally invasive techniques, such as endobronchial ultrasound with transbronchial needle aspiration or/and biopsy (EBUS–TBNA/B), represent the preferred first-line approach for mediastinal staging, before performing mediastinoscopy. We herein aimed to evaluate the negative predictive value (NPV) of EBUS-TBNA in a tertiary referral center and correlate NPV with primary tumor features and other clinicopathological variables.

      Method

      We retrospectively studied the medical records of 20 patients with resectable NSCLC, submitted, from January 2017 to January 2018, to EBUS-TBNA in the Department of Interventional Pulmonology of the first Pulmonology Clinic of Sotiria Athens General Hospital; EBUS-TBNA had been performed prior to surgical resection of the primary tumor and surgical lymph node staging in all patients. The EBUS-TBNA results were correlated with surgical staging.

      Result

      Among all lumph node stations sampled, there were 46 with negative EBUS-TBNA results. Post-operatively, 6 EBUS-TBNA negative lymph nodes were re-staged as positive. The remaining 40 EBUS-TBNA negative nodes were true negative, as confirmed by surgical staging. NPV of EBUS-TBNA was 87%, and thus within the range of previously published results. Among cases with negative ΕΒUS-TBNA results, a statistically significant correlation was observed between low NPV (false negative EBUS-TBNA) and T3 tumor size (> 7cm), pre-bronchoscopy N2 disease, presence of necrosis within the primary tumor, and microscopic vascular invasion (p-value <0.05 in all cases).

      Conclusion

      Patients with Τ3 tumors (>7cm), Ν2 disease before the performance of EBUS-TBNA, and those with tumor necrosis or microscopic vascular invasion may be at greater risk for false negative EBUS-TBNA results. Given the small sample size of our study and its retrospective study design, it must be emphasized that these findings are highly preliminary and must be confirmed in larger prospective series.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.